INTUITIVE SURGICAL INC SEC 10-Q Report

Intuitive Surgical Inc., a global leader in robotic-assisted minimally invasive surgery, has released its latest Form 10-Q report, showcasing robust financial and operational performance. The company's innovative da Vinci surgical systems and Ion endoluminal system continue to drive growth, reflecting its commitment to advancing surgical technology and expanding its market presence.

Financial Highlights

Intuitive Surgical Inc. reported impressive financial results for the latest quarter, demonstrating significant growth across key metrics:

• Total Revenue: $2,440.0 million, a substantial increase from $2,009.9 million in the same period last year, driven by growth in both product and service revenues.
• Gross Profit: $1,617.9 million, up from $1,372.7 million, indicating improved cost management and higher sales volume.
• Income from Operations: $743.4 million, compared to $567.3 million, showcasing enhanced operational efficiency and effective cost control.
• Net Income: $664.2 million, an increase from $531.5 million, highlighting strong financial performance and profitability.
• Net Income Per Share (Diluted): $1.81, up from $1.46, reflecting the company's ability to generate higher earnings per share.

Business Highlights

Intuitive Surgical Inc. continues to excel in its business operations, with notable achievements and strategic initiatives:

• Revenue Segments: The company reported revenue from its da Vinci surgical systems, instruments and accessories, and service offerings. The da Vinci systems include the da Vinci 5, da Vinci X, da Vinci Xi, and da Vinci SP surgical systems, each contributing to the overall revenue. The Ion endoluminal system also adds to the revenue stream, focusing on minimally invasive biopsies in the lung.
• Geographical Performance: Domestic revenue accounted for 67% of total revenue, while revenue from outside the U.S. (OUS) markets accounted for 33%. The company continues to expand its presence in international markets, with regulatory clearances obtained in South Korea, Japan, and Europe for various systems.
• Sales Units: As of June 30, 2025, the company has an installed base of 689 da Vinci 5 surgical systems and 314 da Vinci SP surgical systems. The phased launch of the da Vinci 5 surgical system is ongoing, with a focus on maturing supply and manufacturing processes.
• New Product Launches: The company launched the da Vinci 5 surgical system, which received regulatory clearances in multiple regions, including the U.S., South Korea, Japan, and Europe. The system is designed for use in a wide range of surgical specialties and procedures.
• Future Outlook: The company is focused on expanding access to high-quality minimally invasive care and plans to seek additional regulatory clearances for its Ion endoluminal system in OUS markets. The phased launch of the da Vinci 5 surgical system is expected to continue over several quarters.

SEC Filing: INTUITIVE SURGICAL INC [ ISRG ] - 10-Q - Jul. 23, 2025